Zobrazeno 1 - 10 of 100 pro vyhledávání: '"Joan R, Butterton"'
1
Akademický článek
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
Autor: Jean-François Timsit, Jennifer A. Huntington, Richard G. Wunderink, Nobuaki Shime, Marin H. Kollef, Ülo Kivistik, Martin Nováček, Álvaro Réa-Neto, Ignacio Martin-Loeches, Brian Yu, Erin H. Jensen, Joan R. Butterton, Dominik J. Wolf, Elizabeth G. Rhee, Christopher J. Bruno
Publikováno v: Critical Care, Vol 25, Iss 1, Pp 1-14 (2021)
Abstract Background Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites. Among nosocomial pneumonia subtypes, ventilated HAB
Externí odkaz: https://doaj.org/article/b8ee6048ea624162b18dfef8acdeaed8
Zobrazit plný text záznamu
3
A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
Autor: Richard G. Wunderink, Daniel Gonzalez, Jason Y Kim, Satoshi Fujimi, Martin A. Croce, Natasha Broyde, Carisa De Anda, Joan R. Butterton, Myra W. Popejoy, Antoine Roquilly
Publikováno v: Clinical Infectious Diseases. 73:e710-e718
Background Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are associated with high mortality rates. We evaluated the efficacy and safety of tedizolid (administered as tedizolid phosphate) for treatme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d726141e35a7048e98335b91646b2386
https://doi.org/10.1093/cid/ciab032
Zobrazit plný text záznamu
4
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults
Autor: Christine Fandozzi, Deborah Panebianco, Luzelena Caro, Dennis Wolford, Zifang Guo, Iain P. Fraser, Dennis Swearingen, Vanessa Levine, Hwa-Ping Feng, Thomayant Prueksaritanont, Joan R. Butterton, Marian Iwamoto, Wendy W. Yeh
Publikováno v: Clinical Drug Investigation. 41:133-147
Many people infected with hepatitis C virus have comorbidities, including hypercholesterolemia, that are treated with statins. In this study, we evaluated the drug–drug interaction potential of the hepatitis C virus inhibitors elbasvir (EBR) and gr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6ebcf0ed8c8b4c9cc92692ec75038ce5
https://doi.org/10.1007/s40261-020-00974-8
Zobrazit plný text záznamu
5
Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections
Autor: Carisa De Anda, Mohammed S Tayob, Jason Y Kim, Natasha Broyde, Tinatin Antadze, Borislav Ninov, Pamela Sears, Joan R. Butterton, Margaret Z Chou, John S. Bradley
Publikováno v: Pediatric Infectious Disease Journal. 40:238-244
BACKGROUND Tedizolid phosphate is an oxazolidinone prodrug approved in 2014 for treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs); however, efficacy has not previously been evaluated in children. This study compare
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95fb626110543ce663e36eab62530b0
https://doi.org/10.1097/inf.0000000000003010
Zobrazit plný text záznamu
6
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
Autor: Nicholas A. Kartsonis, Antoine Roquilly, Robert W. Tipping, Luke F Chen, Aileen David-Wang, Richard G. Wunderink, Joan R. Butterton, Daniel Gonzalez, Jiejun Du, Munjal Patel, Keith S Kaye, Katherine Young, Ivan Titov, Michelle L Brown, Maria C Losada, Amanda Paschke, Helen W. Boucher, Matthew L. Rizk
Publikováno v: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background Imipenem combined with the β-lactamase inhibitor relebactam has broad antibacterial activity, including against carbapenem-resistant gram-negative pathogens. We evaluated efficacy and safety of imipenem/cilastatin/relebactam in treating h
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6088cad957d7d5ee0a356936d00a1aec
https://doi.org/10.1093/cid/ciaa803
Zobrazit plný text záznamu
7
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation
Autor: Roy F. Chemaly, Wendy W. Yeh, Per Ljungman, Valerie L Teal, Randi Y. Leavitt, Cyrus Badshah, Hong Wan, Francisco M. Marty, Joan R. Butterton
Publikováno v: American Journal of Transplantation. 20:1703-1711
Letermovir, a cytomegalovirus (CMV) terminase-complex inhibitor, is indicated for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of allogeneic hematopoietic cell transplantation (HCT). In a phase III, double-blind, rand
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cca12ae51a30f4471fd51f6b2f969ea7
https://doi.org/10.1111/ajt.15764
Zobrazit plný text záznamu
10
Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Autor: Martin Nováček, Joan R. Butterton, Ülo Kivistik, Christopher Bruno, Jean-François Timsit, Álvaro Réa-Neto, Ignacio Martin-Loeches, Gina Lin, Elizabeth G. Rhee, Marin H. Kollef, Brian Yu, Richard G. Wunderink, Nobuaki Shime, Jennifer A. Huntington
Publikováno v: The Lancet Infectious Diseases. 19:1299-1311
Nosocomial pneumonia due to antimicrobial-resistant pathogens is associated with high mortality. We assessed the efficacy and safety of the combination antibacterial drug ceftolozane-tazobactam versus meropenem for treatment of Gram-negative nosocomi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93d9884fb39349b489c8f35d05d47c80
https://doi.org/10.1016/s1473-3099(19)30403-7
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje